339 related articles for article (PubMed ID: 37649037)
41. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
42. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
43. Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.
Farhangnia P; Akbarpour M; Yazdanifar M; Aref AR; Delbandi AA; Rezaei N
Expert Rev Clin Immunol; 2022 Dec; 18(12):1217-1237. PubMed ID: 36154551
[TBL] [Abstract][Full Text] [Related]
44. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
45. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
46. HVEM network signaling in cancer.
Šedý JR; Ramezani-Rad P
Adv Cancer Res; 2019; 142():145-186. PubMed ID: 30885361
[TBL] [Abstract][Full Text] [Related]
47. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
48. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
51. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
52. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
53. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
54. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
55. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
56. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Khair DO; Bax HJ; Mele S; Crescioli S; Pellizzari G; Khiabany A; Nakamura M; Harris RJ; French E; Hoffmann RM; Williams IP; Cheung A; Thair B; Beales CT; Touizer E; Signell AW; Tasnova NL; Spicer JF; Josephs DH; Geh JL; MacKenzie Ross A; Healy C; Papa S; Lacy KE; Karagiannis SN
Front Immunol; 2019; 10():453. PubMed ID: 30941125
[TBL] [Abstract][Full Text] [Related]
57. BTLA inhibition has a dominant role in the
Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
Front Immunol; 2022; 13():956694. PubMed ID: 36081508
[TBL] [Abstract][Full Text] [Related]
58. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
59. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.
Wang H; Kaur G; Sankin AI; Chen F; Guan F; Zang X
J Hematol Oncol; 2019 Jun; 12(1):59. PubMed ID: 31186046
[TBL] [Abstract][Full Text] [Related]
60. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
